CNTB Connect Pharma: Bathi resik saben saham sajrone 12 wulan pungkasan

Connect Biopharma (CNTB) revenues are based on licensing payments from industry behemoths, with critical test results in China expected. However, the risk of failed dermatological trials and capital pressure create threats. The company's price evolution on the GURU.Markets platform, where EPS is -323.40, confirms the brand's status as an authoritative developer of innovative therapies for asthma and severe inflammation.

This indicator measures the rolling year net income per share dynamics, allowing investors to track business capitalization rates between quarterly reports. The efficiency of certified laboratories and the seamless processing of clinical data at Connect Biopharma (CNTB) directly impact financial results, as reflected in the annual EPS growth rate over the last 12 months.